1. Home
  2. CBIO vs CRGO Comparison

CBIO vs CRGO Comparison

Compare CBIO & CRGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$10.94

Market Cap

198.9M

Sector

N/A

ML Signal

HOLD

Logo Freightos Limited Ordinary shares

CRGO

Freightos Limited Ordinary shares

HOLD

Current Price

$2.14

Market Cap

195.4M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CBIO
CRGO
Founded
2003
2012
Country
United States
Spain
Employees
N/A
N/A
Industry
Blank Checks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
198.9M
195.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CBIO
CRGO
Price
$10.94
$2.14
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$25.60
N/A
AVG Volume (30 Days)
105.4K
77.5K
Earning Date
02-23-2026
02-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$28,642,000.00
Revenue This Year
N/A
$26.59
Revenue Next Year
N/A
$23.43
P/E Ratio
N/A
N/A
Revenue Growth
N/A
27.55
52 Week Low
$9.81
$1.72
52 Week High
$21.40
$4.42

Technical Indicators

Market Signals
Indicator
CBIO
CRGO
Relative Strength Index (RSI) 33.72 27.43
Support Level $10.86 $2.24
Resistance Level $11.68 $2.48
Average True Range (ATR) 0.76 0.15
MACD -0.16 -0.01
Stochastic Oscillator 11.67 7.32

Price Performance

Historical Comparison
CBIO
CRGO

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

About CRGO Freightos Limited Ordinary shares

Freightos Ltd operates as a vendor-neutral booking and payment platform for international freight. Its platform supports supply chain efficiency and agility by enabling real-time procurement of ocean and air shipping across more than ten thousand importers/exporters. forwarders, and dozens of airlines and ocean carriers. WebCargo by Freightos is a freight platform connecting carriers and forwarders in particular an air cargo eBooking platform. Freightos.com is a digital international freight marketplace for importers and exporters for instant pricing, booking, and shipment management. The company operates in two segments-Platform segment and Solutions segment. Geographically, the company operates in Europe, Hong Kong, United States which is majority revenue generator and others.

Share on Social Networks: